Start a live chat
1-800-870-4800
NMN — what it is,
what the science says,
and why longevity researchers study it.
Nicotinamide mononucleotide has become one of the most studied molecules in contemporary longevity science. Understanding why requires understanding a single biological story: what NAD+ is, why it declines across the human lifespan, and what the research community has spent decades trying to learn about the molecules that precede it in the cellular pathway.
I
The molecule at the center —
what NMN actually is.
Nicotinamide mononucleotide — NMN — is a naturally occurring molecule found in the body and in trace amounts in certain foods. It belongs to a family of compounds known as NAD+ precursors: molecules that the body uses as raw material in the biochemical pathway that produces nicotinamide adenine dinucleotide, or NAD+.
NAD+ is not a curiosity. It is one of the most essential molecules in biology — present in every cell in the body, required for the basic chemistry of energy metabolism, and central to a set of biological processes that researchers have increasingly connected to how cells maintain themselves across time. Without adequate NAD+, cellular function degrades. The processes that depend on it slow, stall, or fail. And one of the most consistent findings in aging biology is that NAD+ levels decline substantially as the human body grows older.
NMN sits one step upstream of NAD+ in the biosynthesis pathway — the Salvage Pathway — that the body uses to produce and recycle the molecule. When NMN enters a cell, it is converted to NAD+ through a single enzymatic step. This directness, relative to other precursor molecules further upstream in the same pathway, is one of the reasons NMN has attracted the sustained attention of researchers studying aging and cellular longevity.
The story of NMN in longevity science is, at its core, the story of NAD+: what it does, why its decline matters, and what researchers have been trying to understand about whether and how that decline can be addressed. To understand why NMN has become one of the most researched molecules in aging science, it is necessary to understand that story from the beginning.
NMN does not exist in isolation.
It exists as a single step
in a cellular story that aging science
has spent decades trying to read.
The Biosynthesis Pathway
How the body produces NAD+ —
and where NMN enters the pathway.
Step 01
Tryptophan & Niacin (B3)
The de novo pathway begins with tryptophan, an amino acid from dietary protein. Niacin (vitamin B3) also enters here. This is the longest route to NAD+ — multiple enzymatic steps, lower efficiency in aging cells.
Step 02
Nicotinamide (NAM)
The Salvage Pathway recycles nicotinamide — a byproduct of NAD+ consumption — back into the biosynthesis cycle. NAMPT, the rate-limiting enzyme in this recycling loop, converts NAM into NMN.
Step 03
NMN
Nicotinamide mononucleotide is the penultimate step. Produced by NAMPT from nicotinamide, NMN sits one enzymatic conversion away from NAD+ itself — the most direct precursor in the Salvage Pathway.
Step 04
NAD+
Nicotinamide adenine dinucleotide — the destination. Required by sirtuins, PARPs, and CD38. Central to energy metabolism, DNA maintenance, and the cellular stress response pathways that longevity research has studied most intensively.
II
Why NAD+ matters —
and what the decline across a lifetime means.
NAD+ is required by three major classes of enzymes that have become central to longevity science research over the past two decades. The first are the sirtuins — a family of seven proteins, named for the yeast gene Silent Information Regulator 2 (Sir2) from which they were originally identified — that researchers have characterized as master regulators of cellular maintenance. Sirtuins govern processes including gene expression, DNA repair coordination, mitochondrial health, and the cellular stress response. They are NAD+-dependent enzymes: without adequate NAD+, their activity is constrained.
The second class is the PARPs — poly(ADP-ribose) polymerases — enzymes that consume NAD+ during the DNA repair process. When cells encounter DNA damage, PARP enzymes activate and draw heavily on the available NAD+ pool to execute the repair response. In aging cells, where DNA damage accumulates and repair demands are higher, PARP activity can become a significant drain on a NAD+ pool that is already diminishing through other mechanisms.
The third is CD38, an enzyme that degrades NAD+ and whose expression has been found to increase substantially with age and with states of chronic inflammation. Research published in Cell Metabolism documented that CD38 levels rise markedly in aged tissues — contributing to what researchers have described as one of the primary drivers of age-related NAD+ decline, distinct from the decline in NAMPT activity that is the other major contributor.
Taken together, the picture that aging biology has assembled over the past several decades is one of progressive NAD+ insufficiency: a molecule that peaks in youth and that the body becomes progressively less capable of maintaining at youthful levels as it ages — through declining production, accelerating consumption, and increasing degradation. It is against this background that NMN research takes on its significance.
The Aging NAD+ System
What changes in the NAD+ system
as the body ages.
High production. Efficient recycling. Adequate supply.
NAMPT activity is high — the Salvage Pathway recycles nicotinamide efficiently
CD38 expression is low — NAD+ degradation is contained
Sirtuin activity is supported — cellular maintenance processes run at capacity
PARP demand is manageable — DNA repair draws on a sufficient NAD+ pool
Mitochondrial function is robust — energy metabolism operates efficiently
Cellular stress response is responsive and rapid
Declining production. Increased demand. Mounting insufficiency.
NAMPT activity declines — the Salvage Pathway becomes less efficient
CD38 expression rises with age and inflammation — NAD+ is degraded faster
Sirtuin activity is constrained by insufficient NAD+ availability
Accumulated DNA damage increases PARP demand on a depleted pool
Mitochondrial function declines alongside falling NAD+ levels
Cellular stress response is slower and less complete
III
The research trajectory —
how NMN went from laboratory molecule to longevity science focus.
NMN did not arrive in aging science fully formed. The molecule's current prominence in longevity research is the product of a decades-long accumulation of findings that began with the basic characterization of NAD+ biology in yeast and nematodes, moved through landmark discoveries in mammalian aging research in the early 2000s, and arrived at the first human clinical trials in the late 2010s and early 2020s.
The pivotal work came from multiple directions simultaneously. Research from David Sinclair's laboratory at Harvard, building on foundational findings about sirtuins and NAD+ in yeast by Leonard Guarente and Shin-ichiro Imai, established that NAD+ decline was not merely a marker of aging but a potential driver of it — and that restoring NAD+ levels in aged animals through precursor supplementation produced measurable changes in biological markers of aging. Work from Shin-ichiro Imai's laboratory at Washington University specifically identified NMN as a particularly effective NAD+ precursor in mouse studies, documenting improvements in energy metabolism, muscle function, eye function, and other age-related parameters.
What distinguished this research from prior work on NAD+ precursors was the combination of mechanistic specificity and physiological scope. Researchers were not observing a single pathway or tissue. They were documenting NAD+ restoration producing coordinated changes across multiple organ systems in aged animals — a breadth of effect that attracted widespread attention from the aging science community and that seeded the research programs now running human clinical trials to examine whether these observations translate to the human biology they are ultimately meant to illuminate.
The human research is still at an early stage relative to what has been established in animal models. That is the honest characterization of where the science stands. What the animal research has produced is a strong mechanistic framework and a consistent pattern of findings compelling enough to justify the substantial investment in human studies now underway. What those studies are working to determine — with the rigor and care that human research requires — is the degree to which the mammalian biology observed in laboratory models reflects the biology of aging people, and what role NAD+ restoration might play in the longevity science of the future.
Key Research Milestones
The scientific trajectory that brought
NMN to the center of longevity research.
These are not clinical claims. They are a summary of the research record — the sequence of scientific findings that established NMN's place in the aging science literature and that form the foundation for the human trials now underway.
Sir2, sirtuins, and the NAD+ connection established in yeast
Foundational research from Guarente and colleagues established that Sir2 — the ancestral sirtuin — requires NAD+ for its activity and is connected to lifespan extension in yeast. This created the conceptual foundation for all subsequent mammalian NAD+ and longevity research. The insight that a longevity-associated enzyme was NAD+-dependent focused the field on the question of NAD+ availability as a determinant of cellular aging processes.
NAMPT identified as the rate-limiting enzyme in mammalian NAD+ biosynthesis
Research from Imai and colleagues identified NAMPT — nicotinamide phosphoribosyltransferase — as the key rate-limiting enzyme controlling the Salvage Pathway in mammals and established its role in producing NMN from nicotinamide. This work mapped the human NAD+ biosynthesis pathway in detail and identified the specific enzymatic step most relevant to NMN's action, laying the groundwork for understanding why NMN, as the direct product of NAMPT, occupies a particularly important position in the pathway.
NAD+ decline identified as a driver of age-related muscle and metabolic deterioration in mice
Research from Imai's laboratory published in Cell demonstrated that NMN administration in aged mice produced substantial changes in energy metabolism, muscle function, bone density, eye function, and immune function — with effects that were mechanistically linked to NAD+ restoration and sirtuin activity. The breadth of these observations across multiple organ systems attracted wide attention and established NMN as a research priority in aging biology, seeding the wave of subsequent animal and human studies.
First published human safety and pharmacokinetics data for NMN
The first published human clinical data for NMN appeared, documenting safety, tolerability, and pharmacokinetics in healthy adults. Research confirmed that orally administered NMN was absorbed, converted to NAD+ metabolites in the bloodstream, and well-tolerated across the doses studied. These findings cleared the path for larger, longer-duration human trials examining the biological effects of NMN supplementation in aging populations — the research now at the forefront of the field.
Multiple human clinical trials underway across cardiovascular, metabolic, cognitive, and aging endpoints
The current era of NMN research is characterized by a substantial and growing body of human clinical trials examining NMN across multiple biological domains — cardiovascular aging, metabolic health, skeletal muscle function, cognitive performance, and biological age markers including epigenetic clocks. These trials are the scientific frontier of NMN research, working to establish what the compelling animal literature means for human aging biology. Results continue to be published, and the field is actively evolving.
The Research in Numbers
What the NMN and NAD+
research record shows.
~50%
Estimated NAD+ decline from young adulthood to middle age in research models
Studies examining NAD+ levels in human tissues have documented substantial age-related decline — with estimates suggesting levels approximately half those of young adults by middle age, continuing to fall thereafter. This pattern of decline is one of the most consistently replicated findings in the aging biology literature. Studies were conducted independently and did not involve any specific Codeage product.
20+
Human clinical trials of NMN published or registered as of the early 2020s
From near-zero human research a decade ago, NMN has generated a rapidly expanding body of human clinical trial data. Trials registered across multiple countries are examining NMN in contexts ranging from metabolic health and muscle aging to cardiovascular biology and epigenetic age markers — a scope of human research that reflects the field's assessment of the molecule's scientific significance.
7
Mammalian sirtuins that depend on NAD+ for their activity
All seven members of the mammalian sirtuin family — SIRT1 through SIRT7 — are NAD+-dependent enzymes. Their combined functions span gene regulation, DNA repair, mitochondrial biogenesis, circadian rhythm maintenance, and metabolic control. The breadth of sirtuin biology is one reason NAD+ availability has such wide implications for cellular function, and one reason the decline of NAD+ with age is studied with such attention in longevity science.
IV
Where the science stands —
what is established, what remains open.
The scientific record on NMN and NAD+ represents one of the most intensive areas of contemporary aging research — but it is worth being precise about what that record contains and what it does not.
What is established, with a high degree of consistency across multiple research groups and model organisms, is that NAD+ levels decline substantially with age; that this decline is associated with impaired function of the NAD+-dependent enzyme systems central to cellular maintenance; and that restoring NAD+ levels in aged animals through precursor administration — including NMN — produces measurable changes in biological markers across multiple organ systems. The mechanistic story is detailed, coherent, and widely accepted in the research community.
What remains at an earlier stage is the human translation of these findings. Human clinical trials of NMN are underway and producing results — pharmacokinetic data confirming absorption and conversion, preliminary observations across metabolic, cardiovascular, and musculoskeletal domains — but the full picture of what NAD+ restoration means for human aging biology is still being assembled by the scientific community. The animal literature is compelling; the human literature is developing; the distance between them is where rigorous science is currently working.
This is the honest scientific position on NMN. Not a molecule whose effects in humans are proven. Not a molecule without a strong scientific foundation. A molecule at the center of one of the most active and substantive areas of contemporary longevity research — one whose biological story is clear enough to justify the sustained investment of major research institutions, and whose human story is being written in the clinical trials currently running. That is the position from which the Codeage approach to NMN and Cellular Longevity is built.
The animal literature is compelling.
The human literature is developing.
The distance between them is where
rigorous science is currently working.
Codeage · Pillar 03 · Cellular Longevity
Built for the
cellular long game.
Cellular Longevity is Pillar 03 of The Longevity Code — the dimension of the system built around NAD+ biology, mitochondrial health, and the science of cellular aging.
Explore Cellular Longevity →
